Dupixent® (dupilumab) fda approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (eoe)

Approval based on phase 3 eoe kids trial showing a greater proportion of children taking dupixent achieved histological remission compared to placebo

REGN Ratings Summary

REGN Quant Ranking